Vote Scores
Filings read through

Aurinia Pharmaceuticals Inc.: how funds voted at the meeting of 14 Jun 2024

Ticker
AUPH
Meeting
Season
year to 30 June 2024
Filers reporting
224
Ballot items
4

224 filers on Form N-PX reported votes at the Aurinia Pharmaceuticals Inc. meeting of 14 Jun 2024. The records fall into 4 ballot items. The page lists them in ballot order: items of the company first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting.

This meeting is in the year to 30 June 2024. The latest season on file is the year to 30 June 2026. The page of Aurinia Pharmaceuticals Inc. has the latest meeting.

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2024. Filings read through . How the figures are made

The ballot

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

  1. Item 1: Director elections

    9 nominees. 87.2% of the reported votes are for. 29 filers withheld from or voted against at least one nominee.

    874 vote records from 58 filers. 1 of the 58 filers that marked the item voted against management.

    • Positions of 27 fund families
    • For 27
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    297 vote records from 220 filers. 126 of the 204 filers that marked the item voted against management. 16 filers gave no management mark.

    • Positions of 33 fund families
    • For 11
    • Against 22
    • Against management 22
  3. Item 3: Audit-related items (auditor ratification)

    98 vote records from 58 filers. 0 of the 58 filers that marked the item voted against management.

    • Positions of 27 fund families
    • For 27
  4. Item 4: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    103 vote records from 61 filers. 3 of the 61 filers that marked the item voted against management.

    • Positions of 27 fund families
    • For 26
    • Against 1
    • Against management 1

Positions of the fund families

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Aurinia Pharmaceuticals Inc., meeting of 14 Jun 2024Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund family2. Say-on-pay3. Auditor
AllianceBernsteinAgainst, against managementNo report
AllspringAgainst, against managementNo report
BlackRock and iSharesForFor
BNY MellonAgainst, against managementNo report
Brighthouse FundsAgainst, against managementFor
Charles SchwabAgainst, against managementFor
Columbia ThreadneedleAgainst, against managementNo report
DWSAgainst, against managementFor
EquitableForFor
Federated HermesForFor
FidelityForFor
Franklin TempletonAgainst, against managementFor
Global XAgainst, against managementFor
Goldman SachsForFor
Guggenheim and RydexAgainst, against managementFor
InvescoAgainst, against managementFor
J.P. MorganAgainst, against managementFor
John Hancock and ManulifeAgainst, against managementFor
Lincoln FinancialForFor
Morgan Stanley, Eaton Vance and CalvertAgainst, against managementFor
NationwideForFor
Neuberger BermanAgainst, against managementNo report
Northern Trust and FlexSharesAgainst, against managementFor
Nuveen and TIAAForFor
Pacific Life fundsForFor
PGIM and PrudentialAgainst, against managementNo report
PrincipalAgainst, against managementFor
ProShares and ProFundsAgainst, against managementFor
SEIAgainst, against managementFor
State Street and SPDRForFor
T. Rowe PriceAgainst, against managementFor
VanguardForFor
VoyaAgainst, against managementFor

Questions

How many filers reported votes at the Aurinia Pharmaceuticals Inc. meeting?
224 Form N-PX filers reported votes at the meeting of 14 Jun 2024. On say-on-pay, 126 of 204 filers that marked the item voted against management (61.8%).
Is this the result of the meeting?
No. The page counts the filers that report on Form N-PX, and the shares they reported. Aurinia Pharmaceuticals Inc. reports the result of a vote on Form 8-K.
Why does the page show counts only for director elections?
A director record names the nominee. This site has no page and no row about a person. For director elections it keeps the number of nominees and the split of votes.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Aurinia Pharmaceuticals Inc. with a meeting date within three days of 14 Jun 2024. A proposal title is the most common wording among filers. Where a wording can name a person, the SEC category is shown. The filers wrote the filings. Filings read through .